METHOD FOR IDENTIFICATION OF ANTI-ALLOGENIC HLA-G ANTIBODIES Russian patent published in 2016 - IPC G01N33/533 

FIELD: medicine.

SUBSTANCE: invention can be used for identification of antibodies to allogenic HLA-G in blood serum. For this purpose, test cross compatibility (cross match) of donor's mononuclear leukocytes with recipient's serum. B-lymphocyte subpopulation are analysed by mononuclear flow cytofluorometry on binding of monoclonal antibodies HLA-G, and degree of expression of HLA-G on test and reference donor's mononuclear cells. At that, significant are subpopulations of CD3^-HLA-G⁺ and CD3⁺HLA-G⁺, from which coefficient of suppressing (CP) in test setting with respect to control by formula: $$C{P}_{\text{HLA-G}}=\frac{\left(HLA-G_{OP}-HLA-G_{CONT}\right)}{HLA-G_{CONT}}\times \mathrm{100,}$$ where HLA-G_op is total relative number of subpopulations expressing HLA-G: (CD3^-HLA-G⁺+CD3⁺HLA-G⁺) in test setting, %; HLA-G_cont is total relative number of subpopulations expressing HLA-G: (CD3^-HLA-G⁺+CD3⁺HLA-G⁺) in control setting, %. Presence of sensitization to allogenic HLA-G is diagnosed at negative value CP_HLA-G.

EFFECT: using given method enables detecting allogeneic sensitisation to HLA-G with help of flow cytometry, determining subpopulation CD3^-HLA-G⁺ and CD3⁺HLA-G⁺.

1 cl, 3 ex, 3 dwg, 2 tbl